Johnson & Johnson (NYSE:JNJ) Shares Acquired by Comprehensive Financial Consultants Institutional Inc.

Comprehensive Financial Consultants Institutional Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,685 shares of the company’s stock after acquiring an additional 1,026 shares during the quarter. Johnson & Johnson makes up 1.6% of Comprehensive Financial Consultants Institutional Inc.’s investment portfolio, making the stock its 11th largest position. Comprehensive Financial Consultants Institutional Inc.’s holdings in Johnson & Johnson were worth $3,399,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. DORCHESTER WEALTH MANAGEMENT Co increased its position in Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after purchasing an additional 414 shares in the last quarter. OneAscent Financial Services LLC boosted its stake in shares of Johnson & Johnson by 82.8% during the 4th quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock worth $1,542,000 after purchasing an additional 4,457 shares during the last quarter. TrueMark Investments LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $1,458,000. RAM Investment Partners LLC raised its position in shares of Johnson & Johnson by 4.5% in the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after buying an additional 73 shares during the last quarter. Finally, RFG Advisory LLC boosted its position in Johnson & Johnson by 12.6% during the third quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock worth $2,921,000 after acquiring an additional 2,102 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.5 %

Shares of JNJ opened at $151.66 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The stock has a market cap of $365.47 billion, a PE ratio of 10.98, a P/E/G ratio of 2.56 and a beta of 0.53. The stock’s 50-day moving average is $157.92 and its two-hundred day moving average is $156.23.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter last year, the company earned $2.35 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent analyst reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Morgan Stanley decreased their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $170.00 to $163.00 in a report on Wednesday, December 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 28th. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.